Exact Sciences (EXAS) Misses Q1 EPS by 12c; maintains guidance

Exact Sciences (NASDAQ: EXAS) reported Q1 EPS of ($0.60), $0.12 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $638 million versus the consensus estimate of $627.35 million.

GUIDANCE:

Exact Sciences sees FY2024 revenue of $2.81-2.85 billion, versus the consensus of $2.833 billion.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Franklin Covey (FC) Misses Q3 EPS by 2c, lowers Guidance
• Greenbrier Cos. (GBX) Reports In-Line Q3 EPS